This newly published report is a global industry analysis on the advanced and targeted drug delivery market that the author forecasts to grow at a 10.4% CAGR to $319 billion by 2021 from $168 billion today. Supported by over 300 tables and figures, this 382 page report is an extensive industry analysis specifically written for C-Suite, VP and Higher executives within the Pharma and Biotech space.
The advanced and targeted drug delivery market is segmented and analysed through to 2021 with corresponding CAGR breakdown by:
- Technology (Nanoparticles, Polymers (micelles, dendrimers etc), Monoclonal antibodies, Gold nanoparticles-based drug delivery and imaging, Drug eluting stents)
- Geography (Global, USA, Europe, RoW)
- Therapeutic Area (Pulmonary, Ocular drug delivery, Ocular nano-based drug delivery implants, Drug Eluting Stents,
- Sub-Market Analysis (details below)
The monoclonal antibody market is further broken down and presented as the top selling mAbs by company, class and revenue through to 2021 with corresponding CAGR values. Specific figures are given in relation to Humira, Remicade, Avastin, Rituxan, Soliris, Herceptin, Kadcyla, Perjeta, Lucentis, Xgeva/Prolia, Stelara and Tysarbi.
The global market for nano-based targeted drug delivery is presented by the following sub-markets liposomes, polymers (micelles, dendrimers etc) and gold nano-particles through to 2021 with corresponding CAGR figures.
The global pulmonary drug delivery market is analysed and presented as metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nebulizers through 2021 with corresponding CAGR data. This market is also divided into the following geographical regions USA, Europe, RoW, Global through 2021 with corresponding CAGR analysis.
The PhD analysts identify breakthrough R&D papers and patents and delve into disruptive technical platforms that is revolutionising drug delivery systems. Business, financial and market analysis is performed on all data collated to yield robust figures and forecast through 2021 with CAGR values. Together, our scientific and business team provides you with their in depth knowledge, experience and perspective on the targeted drug delivery landscape. Stake holder analysis of key players including innovators, developers and commercial partners is performed and an in depth chapter of 170 companies involved is presented. The analysis includes details of how is breakthrough technology adoption is changing the drug delivery landscape and also how emerging products like hydrogels, PEGylated phospholipid nanocarriers and cyclodextrins are disrupting conventional markets.
Key Questions Answered in this Report:
- What are the maximum drug release times reported for various nano-based drug carriers?
- What regulatory agencies are approving specific nanomedicines?
- How many liposome-based drugs are available in the market?
- How many stealth liposomes have been granted market approval?
- How many PEGylated liposomes are used for targeted drug delivery?
- Who are the leading players in liposome-based drug formulation?
- What are stimuli-responsive polymers?
- Who are the market leaders in polymer-based drugs?
- What dendrimer-based drugs are the commercially available for targeted delivery?
- What are the applications of inorganic nanoparticles in targeted drug deliver?
- Which companies are focusing on inorganic nanoparticles for targeted drug delivery?
- What are the applications of magnetic nanoparticles in drug delivery, diagnostic and imaging?
- What is the global market value of nanomedicines?
- What is the global market for nanomedicines by therapeutic areas?
- What is the global market for monoclonal antibodies by geography?
- What are the best-selling mAbs?
- What is the global market for major targeted delivery systems?
1.1 Executive Summary
1.2 About this Report
1.3 Key Questions Answered in this Report
2.0 Targeted Drug Delivery: An Overview
2.1 The Need for Targeted Delivery
2.2 Advantages and Disadvantages of Targeted Drug Delivery
2.3 Types of Drug Targeting
2.3.1 Active Targeting
2.3.2 Passive Targeting
184.108.40.206 Passively Targeted Therapeutic Preparations
220.127.116.11 Polymeric Nanoparticles (NPs) Developed for Passive Delivery of Drugs
2.4 Ideal Characteristics of Targeted Drug Delivery Carriers
2.5 Drug Carriers used in Targeting Systems
3.0 Targeted Drug Delivery and Nanomedicines: An Overview
3.1 Ideal Characteristics of Nanoparticles suited for Targeted Delivery
3.2 Size of Therapeutic Nanoconstructs
3.3 Examples of Nanomedicines Approved by One or More Regulatory Bodies
3.3.1 Brief Description of Approved Nanomedicines
18.104.22.168 Brentuximab Vedotin (Adectris)
22.214.171.124 Trastuzumab Emtansine (Kadcyla)
3.3.2 Therapeutic Nanomedicines in Clinical Trials
3.4 Targeting Approaches of Nanomedicines
3.4.1 Targets of Nanomedicines in the Body
3.4.2 Targeting Ligands
3.5 Mechanism of Internalization of Nanomedicine
3.6 Future Direction of Nanomedicines
3.7 Examples of Nanomedicine Applications
3.8 Rationale for Nanomedicine Approach
3.9 Commercially Available Oral Nanotherapeutics
3.10 Commercially Available Nanotherapeutics for Parenteral Administration
3.11 Examples of FDA-Approved Nanomedicines for Intravenous Route of Administration
3.12 Examples of FDA-Approved Nanomedicines for Pulmonary Route of Administration
3.13 Examples of FDA-Approved Nanomedicines for Subcutaneous, Intramuscular, Transdermal and Ocular Route of Administration
3.14 Examples of Nano-Based Medical Devices and Diagnostics
3.15 Various Types of Nanocarriers Expoited in Formulating Nanomedicines
3.15.1 Types of Nanoparticles
3.16 Use of Nanoparticles in Different Fields of Medicine
3.16.1 Nanosystems for Cancer Treatment
3.16.2 Use of Nanosystems in Tissue Engineering
3.16.3 Use of Nanoparticles (NPs) in Stem Cell Therapy
3.16.4 Use of Nanoparticles in Contrast Agents
3.17 Segmentation of Targeted Drug Delivery Nanosystems
4.0 Lipid-Based Targeted Drug Delivery Nanosystems
4.1 Advantages and Disadvantages of Liposomes as Targeted Drug Delivery Systems
4.2 Classification of Liposomes on the Basis of Size and Composition
4.2.1 Classification of Liposomes on the Basis of Method of Preparation
4.3 Size of Liposomes
4.4 New Generation of Liposomes and their Features
4.5 Conventional Liposomes
4.5.1 Benefits of Drug Loads in Liposomes
4.5.2 Loading Liposomes with Drugs
4.5.3 Intracellular Delivery of Drugs by Liposomes
4.5.4 Liposome-Based Drugs in the Market
4.5.5 Liposome-Based Drugs for Cancer Therapy
4.5.6 Liposomal Drugs in Clinical Trial
4.6 Modified Liposomes
4.6.1 Stealth Liposomes
126.96.36.199 Approved Stealth Liposomes
4.7 Targeted Liposomes
4.7.1 Stimuli-Sensitive Targeted Liposomes
4.7.2 Targeted Liposomal Drugs for Cancer
4.8 Technology Developments in Lipid-Based Carriers
4.9 Key Players Focusing on Lipid-Based Carriers
5.0 Polymer-Based Carriers for Targeted Drug Delivery
5.1 Stimuli-Responsive or Smart Polymers
5.1.1 Temperature-Responsive Polymers
188.8.131.52 Classification of Thermosensitive Polymers
5.1.2 PH-Sensitive Polymers
5.1.3 Bioresponsive Polymers
5.1.4 Field-Responsive Polymers
5.2 Polymer-Based Topical Delivery Systems for Dermatological Diseases
5.2.1 Natural Polymer-Based Topical Delivery Systems
5.2.2 Topical Delivery Systems Based on Synthetic Polymeric Particles
5.3 Clinical Status of Polymeric Nanoparticles in Cancer Treatment
5.4 Polymeric Nanoparticle-Based Therapeutics in Clinical Trials
5.5 Key Players Focusing on Polymer-Based Carriers
6.0 Polymeric Micelle/Co-Polymers for Targeted Drug Delivery
6.1 Substances used to produce Micelle and their Drug Release Duration
6.2 Existing Approaches to Achieve Sustained Release from Micelle
6.2.1 Stimulai-Responsive Micelles
6.3 Passive Targeting of Polymeric Micelle
6.4 Active Targeting of Polymeric Micelle
6.5 Stimuli-Responsive Polymeric Micelles
6.6 Multifunctional Polymeric Micelles
6.6.1 Examples of Multifunctional Drug-Loaded Micelle
6.6.2 Multifunctional Micelles for the Delivery of siRNA
6.7 Drug-Loaded Polymeric Micelle-Based Products in Development
7.0 Dendrimer-Based Targeted Drug Delivery
7.1 Three-Dimensional Structure of Dendrimers
7.2 Dendrions as Multifunctional Nanoplatforms
7.3 Commercially Available and Late-Stage Dendrimers
7.4 Therapeutic Moieties studied using Dendrimer Platform
7.5 Thermosensitive Dendrimers
8.0 Inorganic Nanoparticles for Targeted Drug Delivery
8.1 Companies Focusing on Inorganic Nanoparticles
8.2 Carbon-Based Nanoparticles for Drug Delivery
8.2.1 Carbon Nanotubes (CNTs)
184.108.40.206 Structure of Carbon Nanotubes
220.127.116.11 Artificial Implants from Carbon Nanotubes (CNTs)
18.104.22.168 Detection of Cancer Biomarker by Carbon Nanotubes
22.214.171.124 Drug and Gene Delivery by Carbon Nanotubes
8.3.1 Structure of Fullerene
8.3.2 Biomedical Applications of Fullerenes
8.4 Graphine Oxide (GO) as Nanocarriers
8.4.1 GO for Drug Delivery
8.5 Gold-Based Nanoparticles (AuNPs)
8.5.1 Shapes of Gold Nanoparticles
8.5.2 Imaging Applications of Gold Nanoparticles
8.5.3 Drug Delivery Applications of Gold Nanoparticles
8.5.4 Diagnostic Applications of Gold Nanoparticles
8.6 Silica Nanoparticles for Drug Delivery
8.6.1 Types of Silica Nanoparticles
8.6.2 The Process of Synthesis of SNs
8.6.3 Drugs Delivered through Silica Nanoparticles
8.7 Magnetic Particles for Drug Delivery
8.7.1 Companies Focusing on Magnetic Particles
8.7.2 Typical Design of a Magnetic Nanoparticle
8.7.3 Use of Magnetic Nanoparticles
8.7.4 Diagnostic Use
8.7.5 Coating Materials for Magnetic Nanoparticles
8.7.6 Organic Linkers in Magnetic Nanoparticles
8.7.7 Targeted Magnetic Nanoparticles (MNPs) as Cancer Theranostics
8.7.8 Targeting Magnetic Nanoparticles to Tumors (Passive and Active)
8.7.9 Magnetic Nanoparticles as Diagnostics
8.7.10 Magnetic Nanoparticles as Multimodal Imaging Agents
8.7.11 FDA/EMEA Approved Magnetic Nanoparticle-Based Cotrast Agents
9.0 Cell-Based Systems for Targeted Delivery
9.1 Companies Focusing on Cell-Based Carriers
9.2 Role of Dendritic Cells (DCs) in Drug Delivery
9.3 Engineered RBCs for Drug Delvery
9.3.1 Therapeutic Sites and Targets Accessible for RBC-Delivered Drugs
9.3.2 Examples of Therapeutic Enzymes Encapsulated in Carrier RBCs
9.4 Stem Cells for Drug Delivery
9.5 Bacterial Ghosts for Drug Delivery
10.0 Nucleic Acid/Peptide as Drug Carriers
10.1 `Companies Focusing on Aptamers/Nucleic Acids/Peptides
10.2 Peptide Conjugates for Drug Delivery
10.2.1 Peptides as Radfionuclide Carriers
10.2.3 Peptide Hormones
10.2.4 Peptide Vaccines
10.2.5 Peptide as Cytotoxic Drug Carrier
10.2.6 Cell-Penetrating Peptides
10.2.7 Peptides Applied in Cancer Diagnostics
10.2.8 Peptides Applied in Treating Cancer
10.2.9 Peptide-Based Vaccines in Clinical Development
10.3 DNA/RNA Aptamers
10.3.1 Clinical Use of Aptamers
10.4 DNA Origami (DNA Nanorobots)
11.0 Targeted Therapies by Indication: An Overview
11.1 Targeted Cancer Therapies
11.1.1 Identification of Targets in Cancer Therapy
11.1.2 Categories and Examples of Tumor Antigens
11.1.3 Development of Targeted Therapies for Cancer
11.1.4 Targeted Cancer Therapies in Late Stage Development
11.1.5 Companies Focusing on Oncology Applications of Targeted Drug Delivery
11.2 Monoclonal Antibodies (mAbs) and Targeted Drug Delivery
11.2.1 Monoclonal Antibodies (mAbs)
126.96.36.199 Naked mAbs
188.8.131.52 Examples of Naked mAbs and their Fuctions
184.108.40.206 Conjugated mAbs
220.127.116.11 Bispecific mAbs
11.2.2 U.S./E.U.-Approved mAbs
11.2.3 mAbs by Indication Area
11.2.4 mAb Biosimilars in Late Stage Development
11.2.5 Biosimilar mAbs in Development
11.3 Ocular Applications of Targeted Drug Delivery
11.3.1 Ocular Applications of Dendrimer Systems
11.3.2 Ocular Applications of Liposomes
11.3.3 Micelles in Ocular Drug Delivery
18.104.22.168 Micelle Systems Investigated for Ocular Drug Delivery
11.3.4 Viral and Non-Viral Vectors for Ocular Gene Delivery
11.4 Targeted Drug Delivery for Central Nervous System (CNS) Disorders
11.4.1 Blood Brain Barrier (BBB)
11.4.2 Drug Delivery Approaches and Drug Molecules for Brain
11.4.3 Examples of Nanoparticles (NPs) used for Delivery of Drugs across BBB
11.4.4 Examples of Clinically-Approved NPs Therapeutics for CNS Disorders
11.4.5 Dendrimers for CNS Drug Delivery
11.5 Infectious Disease Applications for Targeted Drug Delivery
11.5.1 Liposomes for Antimicrobial Drug Delivery
11.5.2 Polymeric Nanoparticles for Antimicrobial Drug Delivery
11.5.3 Solid Lipid Nanoparticles (SLNs) for Antimicrobial Drug Delivery
11.5.4 Dendrimers for Antimicrobial Drug Delivery
11.6 Cardiovascular Applications for Targeted Drug Delivery
11.6.1 Nanoparticles for Advanced Diagnostics and Therapy of Cardiovascular Diseases
11.6.2 Therapeutic and Theranostic Nanoparticles for CVD
11.6.3 In vivo Nanosensors for CVD
11.7 Targeted Drug Delivery for Pulmonary Diseases
11.7.1 Drugs for Inhalation
11.7.2 Polymers for Colloidal Pulmonary Drug Delivery Systems
11.7.3 Nebulizers with Novel Technologies for Pulmonary Drug Delivery
11.7.4 Novel Dry Powder Inhalers (DPIs)
11.7.5 Types of Nanoparticles used to Encapsulate API Molecules
11.8 Cosmeceutical Applications of Nano-Based Drugs for Targeted Delivery
12.0 Other Targeted Drug Delivery Technologies
12.1 Ocular Implants
12.1.1 Ocular Implants under Clinical Development
12.1.2 FDA-Approved Ocular Drug Delivery Implants
12.1.3 Sustained Trans-Scleral Ocular Drug Delivery
12.2 Drug Eluting Stents (DES) and Targeted Drug Delivery
12.2.1 Polymers for Stent Coatings
12.3 Microchips: The Novel Implantable Drug Delivery Technology
13.0 Market Analysis to 2021
13.1 Applications of Nanoparticles in Healthcare
13.2 Types of Nanomedicine Companies
13.3 Global Market for Nanomedicines to 2021
13.3.1 Nanomedicines Market by Major Therapeutic Area
13.4 Global Market for Targeted Drug Delivery to 2021
13.4.1 Global Market for mAbs to 2021
22.214.171.124 Best-Selling mAbs 2014-2021
126.96.36.199 Global Market for Humira, Remicade and Avastin
188.8.131.52 Global Market for Rituxan, Soliris and Herceptin
184.108.40.206 Global Market for Kadcyla, Perjeta and Lucentis
220.127.116.11 Global Market for Xgeva/Prolia, Stelara and Tysarbi
13.5 Global Market for Nanoparticle-Based Targeted Drug Delivery Systems to 2021
13.6 Ocular Drug Delivery Market to 2021
13.6.1 Novel Ocular Drug Delivery Systems
18.104.22.168 Ocular Drug Delivery Implants
13.7 Global Market for Implanted Drug Eluting Stents to 2021
13.8 Pulmonary Drug Delivery to 2021
13.9 What does the Future hold for the Targeted Drug Delivery Market?
13.10 Impact of New Technology Systems on the Current Targeted Delivery Market
13.11 Future Directions in Drug Delivery
13.12 Disruptive Technologies within the Existing Targeted Delivery Market
13.12.1 Emergence of Hydrogels in Oral Drug Delivery
13.12.2 Emergence of PEGylated Phospholipid Nanocarriers for Respiratory Diseases
13.12.3 Emergence of Cyclodextrins
22.214.171.124 Cyclodextrins in Oral Drug Delivery
126.96.36.199 Cyclodextrins in Rectal Drug Delivery
188.8.131.52 Cyclodextrin in Nasal Drug Delivery
184.108.40.206 Cyclodextrins in Transdermal Drug Delivery
220.127.116.11 Cyclodextrins in Ocular Drug Delivery
18.104.22.168 Cyclodextrins in Controlled Drug Delivery
14.0 Selected Company Profiles
14.1 3M Company
14.1.1 3M Drug Delivery Systems
14.2 Abbott Laboratories
14.3 Ablynx NV
14.3.1 Nanobody Technology
14.3.2 Clinical Programs
14.3.3 Ablynx’s Partnership with Boehringer Ingelheim
14.3.4 Ablynx’s Partnership with Eddingpharm
14.3.5 Ablynx’s Partnership with Genzyme
14.3.6 Ablynx’s Partnership with Merck & Co.
14.3.7 Ablynx’s Partnership with Merck KGaA
14.3.8 Ablynx’s Partnership with Novartis
14.3.9 Ablynx’s Partnership with Taisho Pharmaceutical
14.4 Aciont Inc.
14.4.1 Visulex Technology
14.5.1 Patchless Patch
14.5.3 Evamist & Lenzetto
14.6 Agilis Biotherapeutics LLC
14.6.1 Agilis’ Engineered DNA Therapeutics
14.6.2 Agilis’ DNA Therapeutic Programs
22.214.171.124 DNA Therapeutics for Friedreich’s Ataxia
126.96.36.199 DNA Therapeutics for Angelman Syndrome (AS)
14.7 Aileron Therapeutics Inc.
14.7.1 P53 Pathway Re-Activator
14.8 Alchemia Oncology Pty Ltd.
14.8.2 HA-Doxorubicin (Hyaluronic acid + Doxorubicin)
14.8.3 HA-5-Fluorouracil (Hyaluronic acid + 5-Fluorouracil)
14.8.4 Monoclonal Antibodies
14.9 Alkermes Pharma Ireland Ltd.
14.9.3 U.S. Products using Alkermes’ Technologies
188.8.131.52 Risperdal Consta
184.108.40.206 Invega Trinza
14.9.4 Alkermes’ Long-Acting Technologies
220.127.116.11 Medisorb Technology
18.104.22.168 LinkeRx Technology
22.214.171.124 NanoCrystal Technology
14.10 Allergan Inc.
14.10.1 Doryx (Delayed-Release Tablets)
14.10.2 Saphris (Sub-Lingual Tablets)
14.10.3 Namenda XR (Extended Release Capsules)
14.10.4 Namzaric (Extended Release Capsule)
14.10.5 Asacol HD (Delayed-Release Tablets)
14.10.6 Delzicol (Delayed-Release Tablets)
14.10.7 Zenpep (Delayed-Release Tablets)
14.11 Alnylam Pharmaceuticals
14.11.1 Development Pipeline
14.11.2 Strategic Alliances
14.12 AmpliPhi Biosciences
14.12.1 Product Pipeline
14.13 Andros Pharmaceuticals Co., Ltd.
14.13.1 High-End Cosmetic Ingredient
14.13.2 Topical Drug Delivery System
14.13.3 Gene Delivery System
14.14 Angiochem Inc.
14.14.1 LRP-1 Technology
14.15 Antares Pharma Inc.
14.15.2 Pen Injectors
14.15.3 Partnered Products
14.16 Aposense Ltd.
14.17 Applied Genetic Technologies Corp. (AGTC)
14.18 Aptagen LLC
14.18.1 Apta-Services (R&D Support)
14.19 Aradigm Corp.
14.19.2 Aradigm’s Product Pipeline
14.20 ArisGen SA
14.20.1 ArisCrown Technology
14.20.2 Sublingual Exenatide ARG011
14.21 Armagen Technologies Inc.
14.21.1 Armagen’s Technology
14.21.2 Armagen’s Licensing and Collaboration Agreement with Shire
14.21.3 Armagen’s Partnership with PacificGMP
14.22 Arrowhead Research Corp.
14.22.1 Arrowhead’s Lead Products
14.22.2 The Dynamic Polyconjugate Platform
14.23 Artificial Cell Technologies Inc.
14.23.2 Respiratory Syncytial Virus (RSV) Vaccine
14.23.3 Malaria Vaccine
14.24 AsclepiX Therapeutics LLC
14.24.1 Anti-Angiogenesis Therapy
14.25 Asklepios BioPharmaceutical Inc.
14.25.1 Asklepios’ Collaboration with Baxter
14.25.2 Asklepios’ Collaboration with Medtronic
14.25.3 Asklepios’ Collaboration with ALS Therapy Development Institute
14.25.4 Asklepios’ Collaboration with Genzyme
14.25.5 Asklepios’ Collaboration with Pfizer
14.26 Astellas Pharma Inc.
14.27 Audentes Therapeutics Inc.
14.28 Avalanche Biotechnologies Inc.
14.28.1 The Ocular BioFactory Platform
14.29 Avita Medical Ltd.
14.29.1 ReCell FOR Burns and Plastics
14.29.2 ReCell for pigmentation
14.29.3 ReCell for Chronic Wounds
14.30 Azaya Therapeutics Inc.
14.31 Bachem Americas Inc.
14.31.1 API Products
14.32 Bayer Pharma AG
14.33 BBB Therapeutics BV
14.33.2 Product Pipeline
14.34 Bespak Europe Ltd.
14.34.1 Inhalation Delivery Devices
14.34.2 Injectable Drug Delivery Devices
14.34.3 VapourSoft Technology
14.34.4 ASI Technology
14.35 Bicycle Therapeutics Ltd.
14.35.1 Bicycle Molecules
14.35.2 R & D in Oncology
14.35.3 R & D in Ophthalmology
14.36 BigDNA Ltd.
14.37 BIND Therapeutics Inc.
14.37.2 BIND Therapeutics’ Intellectual Property
14.37.3 BIND’s Collaboration with Pfizer
14.37.4 BIND’s Collaboration with Merck
14.38 BioDelivery Sciences International Inc.
14.38.1 BEMA Technology
14.38.3 Belbuca (Buprenorphine HCL Buccal Film)
14.38.5 Clonidine Topical Gel
14.39 Bioject Medical Technologies Inc.
14.39.2 Biojector 2000
14.39.3 Bioject Zetajet
14.39.4 Biojet Drug Reconstitution System
14.39.5 Needle-Free Vial Adapter
14.40 BioZone Laboratories Inc.
14.40.1 QuSomes Technology
14.40.2 LipoSpray Technology
14.41 Camurus AB
126.96.36.199 FluidCrystal Injection Depot
188.8.131.52 FluidCrystal Topical Bioadhesive
184.108.40.206 FluidCrystal Nanoparticles
220.127.116.11 CAM2038 (Chronic Pain)
18.104.22.168 Episil Oral Liquid
14.42 Celsion Corp.
14.42.1 Celsion’s LTLD Technology
14.42.2 Celsion’s Pipeline
14.43 CeramiSphere Pty Ltd.
22.214.171.124 Mucosal Delivery of Proteins
126.96.36.199 Delivery of DNA and RNA
188.8.131.52 Delivery of Wound Healing Drugs
14.44 Cerulean Pharma Inc.
14.44.1 Nanoparticle-Drug Conjugates (NDCs)
14.45 Chrysalis BioTherapeutics Inc.
14.45.1 Radiation Therapy (TP508)
14.45.2 Solution for Nuclear Emergencies
14.45.3 Solution for Cardiovascular Disease
14.45.4 Solution for Regenerative Medicine
14.46 Copernicus Therapeutics Inc.
14.47 Cornerstone Pharmaceuticals Inc.
14.47.1 AEMD Platform
14.47.2 Emulsiphan Pipeline
14.48 CureVac AG
14.48.1 CureVac’s RNA Technology Platforms
14.49 CytImmune Sciences Inc.
14.49.4 Partnership with Coldstream Laboratories Inc.
14.50 DepoMed Inc.
14.50.1 Acuform Technology
184.108.40.206 Nucynta ER
14.51 Dicerna Pharmaceuticals
14.51.1 DsiRNA-EX-Conjugate technology
14.51.2 EnCore Lipid Nanoparticles
14.52 Dimension Therapeutics Inc.
14.52.1 Engineered AAV Vectors
14.52.2 Hemophilia Program
14.52.3 Ornithine transcarbamylase (OTC) deficiency
14.52.4 Glycogen Storage Disease Type Ia (GSDIa)
14.53 Dipexium Pharmaceuticals Inc.
14.54 Discovery Laboratories Inc.
14.54.1 AEROSURF – Aerosolized KL4 Sulfactant
14.54.2 KL4 Sulfactant
14.54.3 Capillary Aerosol Generator (CAG) Technology
220.127.116.11 Epigenomic Regulator Program
18.104.22.168 Long-Acting Injectables
22.214.171.124 Abuse Deterrant Technology
126.96.36.199 Transdermal Technology
14.55.3 Products in Development
188.8.131.52 ORADUR – Methylphenidate
14.55.4 Commercial Products
184.108.40.206 ALZET Osmotic Pumps
14.56 EnGeneIC Ltd
14.56.1 EDV Nanocells
14.56.2 Completion of Series B Financing
14.56.3 2015 Thomson Reuters Award
14.56.4 EnGeneIC’s Phase I Clinical Study for Advanced Glioma Patients
14.57 Ensysce Biosciences Inc.
14.57.1 Single-Walled Carbon Nanotubes (SWCNT)
14.57.2 Ensysce’s Product Pipeline
14.58 EryDel SpA
14.58.2 EryDex System
14.59 EryTech Pharma
14.59.4 ERY-ASP (GRASPA)
14.59.5 EryTech’s Key Corporate Facts
14.59.6 Deloitte Award
14.60 Esperance Pharmaceuticals Inc.
14.60.1 MDPs Technology
14.61 Exicure Inc.
14.61.1 SNA Platform
14.62 FIT Biotech Oy
14.62.1 Gene Transfer Unit (GTU) Platform
14.63 Flamel Technologies S.A.
14.63.1 Flamel’s Drug Delivery Platforms
14.63.4 Trigger Lock
14.64 Generex Biotechnology Corp.
14.64.1 RapidMist Technology
14.64.2 Antigen Express Technology
14.64.3 Generex Oral-Lyn
14.65 Genetic Immunity Inc.
14.65 Genus Pharmaceuticals Ltd.
14.66 GenVec Inc.
14.66.1 AdenoVerse Technology
14.67 GlaxoSmithKline LLC
14.67.1 Adavir Diskus
14.68 Glide Pharmaceutical Technologies Ltd.
14.69 Heron Therapeutics Inc.
14.69.1 Biochronomer Technology
14.70 Hoffmann-LaRoche Inc.
14.71 ICB International Inc.
14.71.1 Platform Technology
14.72 iCeutica Inc.
14.72.1 Product Pipeline
14.72.2 SoluMatrix Technology
14.73 ImmusanT Inc.
14.74 InDex Pharmaceuticals AB
14.75 Immune Design
14.76 Immunocore Ltd.
14.77 Inovio Pharmaceuticals
14.77.1 SynCon Technology
14.78 Insite Vision Inc.
14.78.1 DuraSite Technology
14.79 Insmed Inc.
14.80 Intezyne Technologies Inc.
14.80.1 IVECT Method
14.80.2 Intezyne’s Pipeline
14.81 Keystone Nano Inc.
14.81.1 NanoJacket Technology
14.81.2 NanoLiposome Technology
14.82 Kowa Pharmaceuticals America Inc.
14.83 LipimetiX Inc.
14.84 LiPlasome Pharma ApS
14.84.1 LiPlasome’s Pipeline
14.85 Lipocine Inc.
14.85.1 LCPN 1021
14.85.2 LCPN 1111
14.85.3 LPCN 1107
14.85.4 Lip’ral Technology
14.86 Lipotek Pty Ltd.
14.87 Living Cell Technologies Ltd.
14.88 Madison Vaccines Inc.
14.89 MagForce AG
14.89.1 NanoTherm Therapy
14.90 Mankind Pharma Ltd.
14.90.1 Technosphere Technology
14.91 Mersana Therapeutics Inc.
14.91.1 Fleximer Platform
14.91.3 Mersana’s Partnership with Takeda
14.91.4 Mersana’s Partnership with EMD Serono
14.91.5 Mersana’s Partnership with Recepta Biopharma S.A.
14.92 Micochips Biotech Inc.
14.92.3 Current Partnerships
220.127.116.11 Teva Pharmaceuticals
18.104.22.168 Gates Foundation
14.93 Milo Biotechnology LLC
14.94 miRagen Therapeutics Inc.
14.95 Mirna Therapeutics Inc.
14.96 Miros Polymers Inc.
14.96.2 Drug Delivery Systems
14.97 Moderna Therapeutics Inc.
14.97.1 mRNA Expression Platform
14.98 MultiVir Inc.
14.98.1 MultiVir’s Product Candidates
14.99 Mystic Pharmaceuticals Inc.
14.99.1 VersiDoser Delivery Platform
14.99.2 VRx2 Delivery Platform
14.99.3 Intranasal Delivery Systems
14.99.4 Nose to Brain Delivery Systems
14.99.5 Ophthalmic Delivery Systems
14.99.6 Sublingual Delivery Systems
14.101 Nanocarrier Co., Ltd.
14.101.1 Micellar Nanoparticles
14.102 Nanocopoeia Inc.
14.102.1 ElectroNanospray (ENS) Process
14.103 NanoMedical Systems Inc.
14.103.1 Personalized Molecular Drug Delivery System (PMDS)
14.103.2 NanoMedical Diagnostics (NMD)
14.103.3 Multi-Stage NanoVector Drug Delivery System (MSV)
14.104 NanoOncology Inc. (PeptiMed Inc.)
14.104.1 NanoOncology’s Product Pipeline
14.104.2 Ovarian Cancer Program
14.104.3 Breast Cancer Program
14.104.4 Lung Cancer Program
14.105 Nanospectra Biosciences Inc.
14.105.1 AuroLase Therapy
14.106 Nano Precision Medical Inc.
14.106.1 The NanoPortal Solution
14.107 Nanotherapeutics Inc.
14.108 nanoTherics Ltd
14.108.2 Live Cell Alternating Magnetic Field Exposure System (LC-AMF System)
14.108.3 Magnefect System
14.109 NanoVector Inc.
14.109.1 Product Strategy
14.110 NanoViricides Inc.
14.110.1 Platform Technology
14.111 Nektar Therapeutics
14.112 Neos Therapeutics Inc.
14.112.1 Proprietary Technology
14.112.2 Rapidly Disintegrating Ionic Masking
14.112.3 Dynamic Time Release Suspension
14.112.4 Kinetically Controlled Tamper Protection
14.112.5 Currently Marketed Product
14.113 NeXstar Pharmaceuticals Inc.
14.114 NightstaRx Ltd.
14.115 NOD Pharmaceuticals Inc.
14.116 Nordic Nanovector ASA
14.117 Novagali Pharma S.A.
14.117.1 Novasorb Technology
14.118 Novartis Pharmaceuticals Corp.
14.119 Ocular Therapeutix Inc.
14.119.1 ReSure Sealant
14.119.3 Sustained Release Travoprost
14.119.4 Posterior Segment Injections
14.120 Oncolytics Biotech Inc.
14.121 Oxford Biomedica plc
14.121.1 OXB-201 (RetinoStat)
14.121.2 SAR 422459
14.121.3 SAR 421869
14.121.7 OXB-301 (TroVax)
14.121.8 Anti-5T4 Antibody
14.121.9 The LentiVector Platform
14.121.10 5T4 Tumor Antigen
14.121.11 CAR-T Cell Therapy
14.122 PDS Biotechnology Corp.
14.122.1 Versamune NanoPlatform-
14.123 PharmaIN Corp.
14.123.1 Protected Graft Copolymer (PGC)
14.124 PhaseRx Inc.
14.124.1 mRNA Technology
14.125 Phico Therapeutics Ltd.
22.214.171.124 SASPject PT1.2
126.96.36.199 SASPject PT3.1
188.8.131.52 SASPject PT4
14.126 PolyActiva Pty Ltd.
14.126.1 Drug Delivery Platform
14.126.2 Glaucoma Program
14.126.4 Osteoarthritis Program
14.128 PolyTherics Ltd.
14.129 Presage Biosciences Inc.
14.129.1 CIVO Platform
14.130 pSivida Corp.
14.130.1 Durasert Technology
14.130.2 pSivida’s Product Pipeline
14.131 Pulmatrix Inc.
14.132 Quark Pharmaceuticals Inc.
14.132.1 Quark’s siRNA Technology Platform
14.133 Ra Pharmaceuticals Inc.
13.133.2 Factor D Inhibitor
14.134 RaNA Therapeutics Inc.
14.135 RegeneRx Biopharmaceuticals Inc.
14.135.1 Tß4 Peptide Research
14.136 Regenxbio Inc.
14.136.1 NAV Technology
14.137 Renova Therapeutics Inc.
14.138 Replicor Inc.
14.138.1 NAP Technology
14.138.2 Replicor’s Pipeline
184.108.40.206 Phase II Proof of Concept Clinical Study Pipeline
14.138.3 Replicor’s Regulatory Pipeline
14.139 RetroSense Therapeutics LLC
14.140 Rexahn Pharmaceuticals Inc.
14.140.1 Supinoxin (RX-5902)
14.141 RJS Biologics LLC
14.142 Roche Holding AG
14.143 Sarfez Pharmaceuticals Inc.
14.144 Savara Inc.
14.145 Scintipharma Inc.
14.145.1 InteliSite Companion Capsule
14.146 Sequus Pharmaceuticals Inc.
14.147 Serina Therapeutics Inc.
14.147.1 POZ Technology
14.147.2 Serina’s Pipeline
14.148 Serpin Pharma LLC
14.149 Silence Therapeutics PLC
14.150 Silenseed Ltd.
14.150.1 The LODER Platform
14.151 Sylentis SA
14.151.2 SYL 1001
14.152 SoluBest Ltd.
14.152.1 Solumer Technology
14.152.2 Sepomer Technology
14.152.4 Advanced Stage Products
14.152.8 Testosterone undecanoate
14.153 Spark Therapeutics
14.154 Spheringenics Inc.
14.155 Suda Ltd.
14.155.2 ZolpiMist: Insomnia
14.155.3 ArTiMist: Malayria
14.155.4 SUD-001: Migraine
14.155.5 SUD-002: Nausea
14.155.6 SUD-003: Erectile Dysfunction
14.155.7 SUD-004: Pulmonary Arterial Hypertension
14.155.8 SUD-005: Anxiety
14.156 Supratek Pharma Inc.
14.156.1 Biotransport Technology
14.156.2 CombiForm Toolbox
14.156.3 Product Pipeline
14.157 Taiwan Liposome Co. Ltd.
220.127.116.11 Polymeric Mycelle
14.158 TheraSource LLC
14.159 Transgene SA
14.160 Valeant Pharmaceuticals International Inc.
14.161 Vect-Horus S.A.S.
14.161.2 Vect-Horus’ Scientific Collaboration with Servier
14.161.3 Vect-Horus’ Scientific Collaboration with Servier
14.162 Vectura Group plc
14.162.4 Akita Jet
14.162.5 Akita Apixneb
14.163 Vical Inc.
14.163.1 Poloxamer Delivery System
14.163.2 Vaxfectin Adjuvant
14.164 Voyager Therapeutics Inc.
14.165 WAVE Life Sciences Pvt. Ltd.
14.166 Xel Pharmaceuticals
14.166.1 Xel’s Proprietary Drug Delivery Technologies
14.166.2 Transdermal Delivery System
14.166.3 Topical Delivery System
14.166.4 Implant Delivery Systems
14.166.5 Oral Controlled Release
14.166.6 Effervescent Tablet/Lozenge
14.166.7 Cold Water Extraction
14.167 Xenetic Biosciences
14.168 Xigen SA
14.169 Zealand Pharma AS
14.170 Zozano Pharma Corp.
14.170.2 Zozano’s Product Pipeline
INDEX OF FIGURES
Figure 1.1: Summary of Targeted Drug Delivery Market, Through 2021
Figure 2.1: Conventional and Ideal Drug Release Profiles
Figure 2.2: Schematic Representation of Active Targeting
Figure 2.3: Diagrammatic Representation of Passive Targeting
Figure 3.1: Internalization of Nanomedicine
Figure 3.2: Conceptual Visualization of a Future Multifunctional Nanomedicine
Figure 4.1: Classication and Type of Liposomes
Figure 4.2: Diagrammatic Representation of a Liposome
Figure 4.3: Drug Loading Efficiency of Liposomes
Figure 4.4: Intracellular Delivery by pH-Sensitive and Plain Liposomes
Figure 4.5: Schematic Diagram of a Stealth Liposome
Figure 4.6: Schematic of Tumor Targeting Multifunctional Liposome
Figure 4.7: Stimuli Sensitive Multifunctional Targeted Liposome with Low pH Degradable Bonds
Figure 5.1: Delivery of Drugs by Polymers
Figure 6.1: Schematic Diagram Showing Micelle Formation
Figure 6.2: Drug-Loaded Polymeric Micelles with Various Targeting Functions
Figure 6.3: A Hypothetical Polymeric Micelle
Figure 7.1: Three-Dimensional Structure of Dendrimers
Figure 7.2: Dendrimers as Multifunctional Nanoplatforms
Figure 8.1: Mechanism of Antimicrobial Activity of Carbon Nanotubes
Figure 8.2: Trimetalic Nitride Endoherdral Metallofullerene and Empty Cage Fullerene C70
Figure 8.3: Schematic Illustration of Preparation, Drug Loading and Drug Delivery by GO
Figure 8.4 AuNPs with Conjugated Drug
Figure 8.5: Shaped of Gold Nanoparticles
Figure 8.6: Drug Carrying Ability of Silica Nanoparticles
Figure 8.7: A Typical Design of a Magnetic Nanoparticle
Figure 8.8: Shematic Representation of Magnetic Nanoparticles with Surface Modifications
Figure 8.9: Conceptual Representation of MNP Tumor Targeting
Figure 9.1: Schematic Representation of Dendritic Cells Expressing a Number of Different Cell Surface Receptors which are Targets for Antigen Targeting Therapies
Figure 9.2: Therapeutic Sites and Targets Accessible for RBC-Delivered Drugs
Figure 9.3: Procedure of Encapsulating Bacterial Ghost with Drugs
Figure 10.1: Different Possible Treatment Options of Cancer Using Peptides
Figure 10.2: Schematic of Peptide Receptor Radionuclide Therapy (PRRT)
Figure 10.3: Mechanism of Action of Peptide-Based Cancer Vaccines
Figure 10.4: Schematic Diagram of Aptamer Binding to its Target
Figure 10.5: Schematic Diagram of Nanobot for Targeted Drug Delivery
Figure 11.1: Tumor-Associated Antigens (TAA)
Figure 11.2: mAbs binding to Cancer Cells
Figure 11.3: Binding of Naked mAbs to the Antigens on Cancer Cells
Figure 11.4: Schematic Representation of Conjugated mAb
Figure 11.5: Binding of Radiolabeled mAbs to the Cancer Cells
Figure 11.6: A Bispecific mAb
Figure 11.7: Annual U.S./E.U. Approvals of mAbs as of 2015
Figure 11.8: Schematic Illustration of Formation of Spherical Micelle and Drug Encapsulation
Figure 12.1: Microchip Developed by Microchip Biotech
Figure 13.1: Application of Nanotechnology in Healthcare
Figure 13.2: Types of Nanomedicine Companies
Figure 13.3: Global Market for Nanomedicines by Geography, Through 2021
Figure 13.4: Global Market for Nanomedicines by Major Therapeutic Areas, Through 2021
Figure 13.5: Global Targeted Drug Delivery Market, Through 2021
Figure 13.6: Global Market for mAbs by Geography
Figure 13.7: Global Market for Humira, Remicade and Avastin, Throug 2021
Figure 13.8: Global Market for Rituxan, Soliris and Herceptin, Through 2021
Figure 13.9: Global Market for Kadcyla, Perjeta and Lucentis, Through 2021
Figure 13.10: Global Market for Xgeva/Prolia, Stelara and Tysarbi, Through 2021
Figure 13.11: Market for Nano-Based Targeted Drug Delivery Systems by Type, Through 2021
Figure 13.12: Global Market for Novel Ocular Drug Formulations and Implants, Through 2021
Figure 13.13: Global Market for Drug Eluting Stents by Geography, Through 2021
Figure 13.14: Global Market for Pulmonary Drug Delivery Technologies, Through 2021
Figure 14.1: Conventional and Heavy Chain Antibodies
Figure 14.2: Restoration of P53 Activity by Stapled Peptide Dual Inhibitor
Figure 14.3: Andros’ Topical Delivery System
Figure 14.4: Andros’ Gene Delivery System
Figure 14.5: Buccal and Oral Delivery of Peptides by Means of ArisCrown
Figure 14.6: BBB Therapeutics’ G-Technology
Figure 14.7: Components of Accurins
Figure 14.8: Celsion’s LTLD Technology
Figure 14.9: Mechanism of Action of Cerulean’s NDCs
Figure 14.10: Mechanism of Action of EDV Nanocells
Figure 14.11: EryDel’s Technology of Encapsulating Drugs into Erythrocytes
Figure 14.12: ERY-ASP’s Mode of Action
Figure 14.13: Biochronomer Technology
Figure 14.14: IVECT Method of Targeted Drug Delivery
Figure 14.15: Improved Absorption Enabled by Lip’ral Technology
Figure 14.16: Nanocarrier’s Platform Technology
Figure 14.17: Diagrammatic Description of NanoOncology’s Technology
Figure 14.18: Neos Therapeutics’ Ion Exchange Process
Figure 14.19: Mechanism of Action of Betalutin
Figure 14.20: Diagrammatic Representation of PGC
Figure 14.21: PolyActiva’s Drug Polymer Conjugate
Figure 14.22: Interaction between Phosphorothioated NAPs and Amphipathic Protein Targets
Figure 14.23: The Making of Pendent POZ
Figure 14.24: The Making of Pendent POZ-Therapeutics
Figure 14.25: Diagrammatic Structure of Nano-Emulsion
Figure 14.26: Diagrammatic Structure of Polymeric Micelle
Figure 14.27: Diagramatic Representation of Drug Loading in NanoX
Figure 14.28: Diagrammatic Representation of the Specificity of Immunoliposomes
Figure 14.29: Xigen’s ICPT Technology
INDEX OF TABLES
Table 1.1: Summary of Targeted Drug Delivery Market, Through 2021
Table 2.1: A Comparison of Release Obtained from Various Particulate Delivery Systems
Table 2.2: Advantages and Disadvantages of Targeted Drug Delivery
Table 2.3: Examples of Actively Targeted Micelles
Table 2.4: Examples of Passively Targeted Therapeutic Preparations of Polymeric Micelle
Table 2.5: Polymeric Nanoparticles Developed for Passive Delivery of Drugs for Cancer
Table 3.1: Advantages of Nanoparticles in Drug Delivery
Table 3.2: Ideal Drug Delivery Characteristics of Nanodrugs
Table 3.3: Sizes of Some Nanoconstructs used in Therapeutics and Diagnostics
Table 3.4: Examples of Nanomedicines Approved by One or More Regulatory Bodies
Table 3.5: Examples of Nanomedicines Approved by FDA
Table 3.6 Nanoparticle Cancer Therapeutics Undergoing Clinical Investigation
Table 3.7: Passive vs. Active Targeting
Table 3.8: Targets of Nanomedicines in Our Body
Table 3.9: Commonly Available Ligands in Drug Delivery
Table 3.10: Examples of Nanomedicine Applications
Table 3.11: Rationale for Nanotherapeutic Approach
Table 3.12: Commercially Available Nanotherapeutic Products for Oral Administration
Table 3.13: Commercially Available Nanotherapeutics for Parenteral Administration
Table 3.14: Examples of FDA-Approved Nanomedicines for Intravenous Route of Administration
Table 3.15: Examples of FDA-Approved Nanomedicines for Pulmonary Route of Administration
Table 3.16: Examples of FDA-Approved Nanomedicines for Subcutaneous, Intramuscular, Transdermal and Ocular Route of Administration
Table 3.17: Examples of Nano-Based Medical Devices and Diagnostics
Table 3.18: Different Types of Nanocarriers used in Formulating Nanomedicines
Table 3.19: Different Types of Synthesized Nanoforms used in Biomedical Field
Table 3.20: Use of Nanoparticles in Different Fields of Medicine
Table 3.21: Marketed Nanosystems for Cancer Treatment
Table 3.22: Synthetic Nanomaterials used in Tissue Engineering
Table 3.23: Natural Nanomaterials Used in Tissue Engineering
Table 3.24: Examples of NPs-Based Gene Delivery in Stem Cells
Table 3.25: Examples of Contrast Agents using Nanoparticles
Table 4.1: Advantages and Disadvantages of Liposomes as Targeted Systems
Table 4.2: Classification of liposomes on the Basis of Size
Table 4.3: Classification of Liposomes on the Basis of Method of Preparation
Table 4.4: Sizes of Liposomes
Table 4.5: New Generation of Liposomes and their Features
Table 4.6: Benefits of Drug Loads in Liposomes
Table 4.7: Representative List of Liposome-Based Drugs
Table 4.8: Liposome-Based Drugs for Cancer Therapy
Table 4.9: List of Liposomal Drugs in Clinical Trial
Table 4.10: Different Modifications in Liposomes for Improved Drug Delivery
Table 4.11: Approved Stealth Liposome Formulations
Table 4.12: Examples of Ligands used for Targeting of Liposomal Nanocarriers
Table 4.13: Examples of PEGylated Liposomes used for Active Targeting
Table 5.1: Advantages and Disadvantages of Polymer-Based Carriers
Table 5.2: Various Stimuli and Responsive Polymeric Materials
Table 5.3: Various Smart Polymeric Drug Delivery Systems
Table 5.4: Applications of Thermosensitive Polymers for Drug Delivery Systems
Table 5.5: Classification, Representative Thermosensitive Polymers and their Applications
Table 5.6: Various Applications of pH Sensitive Polymeric Drug Delivery Systems
Table 5.7: Applications of Bioresponsive Polymers
Table 5.8: Examples of Natural Polymer-Based Topical Delivery Systems
Table 5.9: Examples of Topical Delivery Systems Based on Synthetic Polymers
Table 5.10: Clinically Approved Polymeric Nanomedicine for Cancer Treatment
Table 5.11: Polymeric Nanoparticle-Based Therapeutics Undergoing Clinical Investigation
Table 6.1 Materials Used to Prepare Micelles and the Release Obtained from these Micelles
Table 6.2: Some Existing Approaches to Achieve Sustained Release from Micelle
Table 6.3 Examples of Stimuli-Responsive Micelles
Table 6.4: Passively-Targeted Therapeutic Formulations of Polymeric Micelle
Table 6.5: Examples of Actively Targeted Micelle
Table 6.6: Examples of Stimuli-Responsive Polymeric Micelles
Table 6.7: Examples of Multifunctional Drug-Loaded Micelles
Table 6.8: Examples of Multifunctional siRNA-Loaded Micelles
Table 6.9: Representative List of Drug-Loaded Polymeric Micelle-Based Products
Table 7.3: List of Commercially Available Dendrimers and Dendrimer-Based Products
Table 7.4: Therapeutic Moities Studied using Dendrimers
Table 7.5: Types of Thermosensitive Dendrimers
Table 8.1: Advantages and Disadvantages of Inorganic Nanoparticles
Table 8.2: Carbon-Based Nanoparticles as Antimicrobial Agents
Table 8.3: Comparison between MWCNT and SWCNT
Table 8.4: Applications of Nanotubes as Artificial Implants
Table 8.5: Examples of Carbon Nanotubes used for the Detection of Cancer Biomarkers
Table 8.6: Examples of Drugs and Nucleic acids Delivered by Carbon Nanotubes
Table 8.7: Summary of Biomedical Applications of Fullerenes
Table 8.8: Drug and Gene Delivery Applications of GO-Based Vehicles
Table 8.9: Imaging Applications of Gold Nanoparticles
Table 8.10: Drug Delivery Applications of Gold Nanoparticles
Table 8.11: Diagnostic Applications of Gold Nanoparticles
Table 8.12: Types of Silica Nanoparticles with their Internal Structure and Pore Diameter
Table 8.13: Common Chemical Constituents used in the Preparation of Silica Nanoparticles
Table 8.14: Types of Drugs Delivered through Silica Nanoparticles
Table 8.15: Advantages and Disadvantages of Magnetic Particles
Table 8.16: Magnetic Nanoparticles used in Biomedical Applications
Table 8.17: Examples of Coating Materials of Magnetic Nanoparticles
Table 8.18: Examples of Organic Linkers and their Applications in Magnetic Nanoparticles
Table 8.19: Commercially Available Magnetic Nanoparticles (Approved or in Clinical Trials)
Table 8.20: Clinical Trials Evaluating the Utility of Magnetic Nanoparticles as Diagnostics
Table 8.21: FDA/EMEA-Approved Magnetic Nanoparticle-Based Contrast Agents
Table 9.1: Advantages and Disadvantages of Cell-Based Systems
Table 9.2: Comparison of RBCs with other Drug Delivery Systems
Table 9.3: Examples of Therapeutic Enzymes Encapsulated in Carrier RBCs
Table 9.4: Clinical and Experimental Therapies using MSCs for Neural-Related Diseases
Table 10.1: Advantages and Disadvantages of Nucleic Acid/Peptide Carriers
Table 10.2: LHRH Agonists and New Generation Agonists Available in the Market
Table 10.3: Peptide Receptors having Potential in Cancer Therapy
Table 10.4: Types and Examples of Cell-Penetrating Peptides
Table 10.5: Peptides Applied in Cancer Diagnosis
Table 10.6: Examples of Peptides Applied in Treating Cancer
Table 10.7: Peptide-Based Vaccines in Development
Table 10.8: The Lone Approved Aptamer and other Aptamers in Development
Table 11.1: Current Targeted Drug Delivery Technologies for Cancer
Table 11.2: Categories and Examples of Tumor Antigens
Table 11.3: Examples of FDA-Approved Targeted Cancer Therapies
Table 11.4: Selected Cancer Therapies in Late Stage Development
Table 11.5: A Representative List of Naked mAbs
Table 11.6: Representative List of Conjugated mAbs
Table 11.7: Approved Antibody ARCs and ADCs
Table 10.8: Representative List of Bispecific mAbs (bsAbs)
Table 11.9: mAbs by Indication Area
Table 11.10: Late Stage mAb Biosimilar Development Activity
Table 11.11: Number of Biosimilars of Monoclonal Antibodies in Development
Table 11.12: Ocular Applications of Dendrimer Drug Delivery Systems
Table 11.13: Applications of Liposomes for Ocular Diseases
Table 11.14: List of Micellar Formulation of Ocular Drugs for Ocular Drug Delivery
Table 11.15: Viral and Non-Viral Systems for Ocular Delivery of Genes
Table 11.16: Different Types of Drug Delivery Methods for CNS Protection
Table 11.17: Drug Delivery Approaches and Drug Molecules for Brain
Table 11.18: Examples of Nanoparticles (NPs) used for Delivery of Drugs across BBB
Table 11.19: Examples of Clinically-Approved NPs Therapeutics for CNS Disorders
Table 11.20: Examples of Nanoparticle-Based Therapeutics for CNS in Clinical Trials
Table 11.21: Examples of Drugs Delivered through PAMAM Dendrimers for CNS
Table 11.22: Liposomes for Antimicrobial Drug Delivery
Table 11.23: Polymeric Nanoparticles for Antimicrobial Drug Delivery
Table 11.24: Solid Lipid Nanoparticles for Antimicrobial Drug Delivery
Table 11.25: Dendrimers for Antimicrobial Drug Delivery
Table 11.26: Examples of Contrast-Enhancing Nanoparticles for Cardiovascular Imaging
Table 11.27 Therapeutic and Theranostic Nanoparticles for CVD
Table 11.28: Nano-Based In vivo CVD Sensors
Table 11.29: Examples of Drugs used for Pulmonary Delivery using Colloidal Carrier Self-Assembling Systems
Table 11.30: Examples of Polymers for Colloidal Pulmonary Drug Delivery Systems
Table 11.31: Examples of Nebulizers with Novel Technologies
Table 11.32: Novel Dry Powder Inhalers Launched in the Past Decade
Table 11.33: Different API Molecules Incorporated into Different Nanoparticle Systems for Pulmonary Application
Table 11.34: Various Nano-Based Cosmeceutical Products in the Market
Table 12.1: Examples of Sustained Release Delivery Systems Studied in Glaucoma-Induced Preclinical Models
Table 12.2: Examples of Sustained Release Delivery Systems for Glaucoma that are Under Clinical Development
Table 12.3: Examples of FDA-Approved Ocular Drug Delivery Implants
Table 12.4: Delivery Systems Suitable for Sustained Trans-Scleral Drug Delivery for Retinal Disorders
Table 12.5: Examples of Drug Eluting Stents Available in the Market
Table 12.6: An Additional List of Polymer-Coated Stents
Table 13.1: Global Nanomedicines Market, Through 2021
Table 13.2: Global Nanomedicines Market by Therapeutic Area, Through 2021
Table 13.3: Global Targeted Drug Delivery Market, Through 2021
Table 13.4 Global Market for mAbs by Geography
Table 13.5: Global Market for Top Selling mAbs by Company, Class and Revenue Through 2021
Table 13.6: Global Market for Nano-Based Targeted Drug Delivery Market by Type, Through 2021
Table 13.7 Nanoparticles used in the Formulation of Ocular Drugs
Table 13.8: Liposomes used in the Formulation of Ocular Drugs
Table 13.9: Dendrimers Investigated for Ocular Drug Delivery
Table 13.10: Global Market for Ocular Drug Delivery, Through 2012
Table 13.11: Global Market for Ocular Drug Delivery by Geography, Through 2012
Table 13.12: Global Market for Drug Eluting Stents, Through 2021
Table 13.13: Global Market for Pulmonary Drug Delivery Technologies, Through 2021
Table 13.14: Global Market for Pulmonary Drug Delivery Technologies by Geography, Through 2021
Table 13.15: Hydrogel Systems with Polymers Examples for Oral Drug Delivery
Table 13.16: Examples of PEGylated Nanocarriers Studied in Rodent Models
Table 13.17: Cyclodextrins for Oral Drug Delivery
Table 13.18: Drugs Tested with Cyclodextrins for Rectal Delivery
Table 13.19: Drugs Tested with Cyclodextrins for Nasal Delivery
Table 13.20: Drugs Tested with Cyclodextrins for Transdermal Delivery
Table 13.21: Drugs Tested with Cyclodextrins for Ocular Drug Delivery
Table 13.22: Drugs Tested with Cyclodextrins for Controlled Drug Delivery
Table 14.1: Ablynx’s Clinical Programs
Table 14.2: Aciont’s Product Pipeline
Table 14.3: Alchemia’s Product Pipeline
Table 14.4: Alkermes’ Product Pipeline
Table 14.5: Alnylam’s Product Pipeline
Table 14.6: AmpliPhi’s Product Pipeline
Table 14.7: Angiochem’s Product Pipeline
Table 14.8: AGTC’s Product Pipeline
Table 14.9: Aradigm’s Product Pipeline
Table 14.10: Armagen’s Lysogen Storage Disorder Pipeline
Table 14.11: Armagen’s Neurodegenerative Pipeline
Table 14.12: Arrowhead’s Pipeline
Table 14.13: Asklepios’ Product Pipeline
Table 14.14: Audentes’ Product Pipeline
Table 14.15: Avalanche’s Product Pipeline
Table 14.16: BBB’s Product Pipeline
Table 14.17: BIND Therapeutics’ Intellectual Property
Table 14.18: Camurus’ Product Pipeline
Table 14.19: Celsion’s Pipeline
Table 14.20: Cerulean’s Product Pipeline
Table 14.21: Copernicus’ Product Pipeline
Table 14.22: CureVac’s Product Pipeline
Table 14.23: Discovery Lab’s Product Pipeline
Table 14.24: DURECT’s Product Pipeline
Table 14.25: Ensyce’s Product Pipeline
Table 14.26: Overview of EryTech’s Development Projects
Table 14.27: EryTech’s Financial Data
Table 14.28: Esperance’s Product Pipeline
Table 14.29: Exicure’s Product Pipeline
Table 14.30 GenVec’s Product Pipeline
Table 14.31: Glide’s Development Programs
Table 14.32: Heron’s Product Pipeline
Table 14.33: iCeutica’s Pain & Inflammation Product Pipeline
Table 14.34: iCeutica’s Oncology Drug Pipeline
Table 14.35: iCeutica’s Respiratory Drug Pipeline
Table 14.36: iCeutica’s Migraine Drug Pipeline
Table 14.37: ImmusanT’s Product Pipeline
Table 14.38: InDex’s Product Pipeline
Table 14.39: Immune Design’s Product Pipeline
Table 14.40: Immunocore’s Product Pipeline
Table 14.41: Inovio’s Product Pipeline
Table 14.42: Insight Vision’s Product Pipeline
Table 14.43: Insmed’s Product Pipeline
Table 14.44: Intezyne’s Pipeline
Table 14.45: LipimetiX’s Product Pipeline
Table 14.46: LiPlasome’s Pipeline
Table 14.47: Lipocine’s Product Pipeline
Table 14.48: Lipotek’s R&D Program
Table 14.49: Madison’s Product Pipeline
Table 14.50: Mersana’s Product Pipeline
Table 14.51: Milo’s Product Pipeline
Table 14.52: miRagen’s Product Pipeline
Table 14.53: MultiVir’s Product Pipeline
Table 14.54: Nanocarrier’s Product Pipeline
Table 14.55: Nanotherapeutics’ Product Pipeline
Table 14.56: NanoViricides’ Product Pipeline
Table 14.57: Nektar’s Approved Products
Table 14.58: Nektar’s Product Pipeline
Table 14.59: Neos Therapeutics’ Product Candidates
Table 14.60: NOD’s Product Pipeline
Table 14.61: Oxford Biomedica’s Product Pipeline
Table 14.62: PDS’ Product Pipeline
Table 14.63: PharmaIN’s Product Pipeline
Table 14.64: PhaseRx’s Product Pipeline
Table 14.65: pSivida’s Product Pipeline
Table 14.66: Pulmatrix’s Product Pipeline
Table 14.67: Quark’s Pipeline of Products
Table 14.68: RaNA’s Product Pipeline
Table 14.69: RegeneRx’s Product Pipeline
Table 14.70: Regenxbio’s Product Pipeline
Table 14.71: Renova Therapeutics’ Product Pipeline
Table 14.72: Replicor’s Phase II Proof of Concept Clinical Study Pipeline
Table 14.73: Replicor’s Regulatory Pipeline
Table 14.74: RJS Biologics’ Product Pipeline
Table 14.75: Sarfez’s Product Pipeline
Table 14.76: Savara’s Product Pipeline
Table 13.77: Serin’a Pipeline
Table 14.78: Silence’s Product Pipeline
Table:14.79: Silenseed’s Product Pipeline
Table 14.80: Sylentis’ Product Pipeline
Table 14.81: Spark’s Product Pipeline
Table 14.82: Transgene’s Product Pipeline
Table 14.83: Vect-Horus’ Product Pipeline
Table 14.84: Vectura’s Pipeline Assets
Table 14.85: Vicas’ Product Pipeline
Table 14.86: Voyager’s Product Pipeline
Table 14.87: WAVE’s Product Pipeline
Table 14.88: Xel’s Pipeline
Table 14.89: Xenetic Biosciences’ Product Pipeline
Table 14.90: Xigen’s Product Pipeline
Table 14.91: Zealand Pharma’s Product Pipeline
Table 14.92: Zozano’s Product Pipeline
- Abbott Laboratories
- Ablynx NV
- Aciont Inc.
- Agilis Biotherapeutics LLC
- Aileron Therapeutics Inc.
- Alchemia Oncology Pty Ltd.
- Alkermes Pharma Ireland Ltd.
- Allergan Inc.
- Alnylam Pharmaceuticals
- AmpliPhi Biosciences
- Andros Pharmaceuticals Co., Ltd.
- Angiochem Inc.
- Antares Pharma Inc.
- Aposense Ltd.
- Applied Genetic Technologies Corp. (AGTC)
- Aptagen LLC
- Aradigm Corp.
- ArisGen SA
- Armagen Technologies Inc.
- Arrowhead Research Corp.
- Artificial Cell Technologies Inc.
- AsclepiX Therapeutics LLC
- Asklepios BioPharmaceutical Inc.
- Astellas Pharma Inc.
- Audentes Therapeutics Inc.
- Avalanche Biotechnologies Inc.
- Avita Medical Ltd.
- Azaya Therapeutics Inc.
- Bachem Americas Inc.
- Bayer Pharma AG
- BBB Therapeutics BV
- Bespak Europe Ltd.
- Bicycle Therapeutics Ltd.
- BigDNA Ltd.
- BIND Therapeutics Inc.
- BioDelivery Sciences International Inc.
- Bioject Medical Technologies Inc.
- BioZone Laboratories Inc.
- Camurus AB
- Celsion Corp.
- CeramiSphere Pty Ltd.
- Cerulean Pharma Inc.
- Chrysalis BioTherapeutics Inc.
- Copernicus Therapeutics Inc.
- Cornerstone Pharmaceuticals Inc.
- CureVac AG
- CytImmune Sciences Inc.
- DepoMed Inc.
- Dicerna Pharmaceuticals
- Dimension Therapeutics Inc.
- Dipexium Pharmaceuticals Inc.
- Discovery Laboratories Inc.
- EnGeneIC Ltd
- Ensysce Biosciences Inc.
- EryDel SpA
- EryTech Pharma
- Esperance Pharmaceuticals Inc.
- Exicure Inc.
- FIT Biotech Oy
- Flamel Technologies S.A.
- Generex Biotechnology Corp.
- Genetic Immunity Inc.
- Genus Pharmaceuticals Ltd.
- GenVec Inc.
- GlaxoSmithKline LLC
- Glide Pharmaceutical Technologies Ltd.
- Heron Therapeutics Inc.
- Hoffmann-LaRoche Inc.
- ICB International Inc.
- iCeutica Inc.
- ImmusanT Inc.
- InDex Pharmaceuticals AB
- Immune Design
- Immunocore Ltd.
- Inovio Pharmaceuticals
- Insite Vision Inc.
- Insmed Inc.
- Intezyne Technologies Inc.
- Keystone Nano Inc.
- Kowa Pharmaceuticals America Inc.
- LipimetiX Inc.
- LiPlasome Pharma ApS
- Lipocine Inc.
- Lipotek Pty Ltd.
- Living Cell Technologies Ltd.
- MagForce AG
- Mankind Pharma Ltd.
- Mersana Therapeutics Inc.
- Micochips Biotech Inc.
- Milo Biotechnology LLC
- miRagen Therapeutics Inc.
- Mirna Therapeutics Inc.
- Miros Polymers Inc.
- Moderna Therapeutics Inc.
- MultiVir Inc.
- Mystic Pharmaceuticals Inc.
- Nanocarrier Co., Ltd.
- Nanocopoeia Inc.
- NanoMedical Systems Inc.
- NanoOncology Inc. (PeptiMed Inc.)
- Nanospectra Biosciences Inc.
- Nano Precision Medical Inc.
- Nanotherapeutics Inc.
- nanoTherics Ltd
- Magnefect System
- NanoVector Inc.
- NanoViricides Inc.
- Nektar Therapeutics
- Neos Therapeutics Inc.
- NeXstar Pharmaceuticals Inc.
- NightstaRx Ltd.
- NOD Pharmaceuticals Inc.
- Nordic Nanovector ASA
- Novagali Pharma S.A.
- Novasorb Technology
- Novartis Pharmaceuticals Corp.
- Ocular Therapeutix Inc.
- Oncolytics Biotech Inc.
- Oxford Biomedica plc
- PDS Biotechnology Corp.
- PharmaIN Corp.
- PhaseRx Inc.
- Phico Therapeutics Ltd.
- PolyActiva Pty Ltd.
- PolyTherics Ltd.
- Presage Biosciences Inc.
- pSivida Corp.
- Pulmatrix Inc.
- Quark Pharmaceuticals Inc.
- Ra Pharmaceuticals Inc.
- RaNA Therapeutics Inc.
- RegeneRx Biopharmaceuticals Inc.
- Regenxbio Inc.
- Renova Therapeutics Inc.
- Replicor Inc.
- RetroSense Therapeutics LLC
- Rexahn Pharmaceuticals Inc.
- RJS Biologics LLC
- Roche Holding AG
- Sarfez Pharmaceuticals Inc.
- Savara Inc.
- Scintipharma Inc.
- Sequus Pharmaceuticals Inc.
- Serina Therapeutics Inc.
- Serpin Pharma LLC
- Silence Therapeutics PLC
- Silenseed Ltd.
- Sylentis SA
- SoluBest Ltd.
- Spark Therapeutics
- Spheringenics Inc.
- Suda Ltd.
- Supratek Pharma Inc.
- Taiwan Liposome Co. Ltd.
- TheraSource LLC
- Transgene SA
- Valeant Pharmaceuticals International Inc.
- Vect-Horus S.A.S.
- Vectura Group plc
- Vical Inc.
- Voyager Therapeutics Inc.
- WAVE Life Sciences Pvt. Ltd.
- Xel Pharmaceuticals
- Xenetic Biosciences
- Xigen SA
- Zealand Pharma AS
- Zozano Pharma Corp
Based on Locations in Europe and Asia, the analyst team are all PhD-level experts and industry-experienced professionals. They pool resources, contacts, business acumen, and technical experience to provide cutting edge insights for all of the reports. The senior analysts have at least ten years’ experience in major strategic corporations such as BCC research and TriMarkPublications. The methodologies are clearly defined from the outset. Initially, a number of clear objectives are set, e.g., to identify the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments:
- By Company
- By Geography (US, UK, EU, Asia)
- By Segment
- By Sub-market
Key Strengths, Weaknesses and Threats InfluencingLeading Player Position within the Market
- Technologies Driving the Market
- Top Fastest Growing Market Segments and Emerging Opportunities
- Top Pharmaceutical Companies within the IPM by Market Share and Revenue
- Comprehensive Product Portfolios, R&D Activity, and Pipeline Therapeutics
- M&A Activity and Future Strategies of Top Personalized Medicine Pharmacos
Following this, the analyst determines key financial data & business strategy information to give clients the most accurate information required to identify areas of profitable growth and what technical advantages are required in a competitive landscape such as company financials, sales & revenue figures.
Market analysis is initiated using primary research tools such as speaking directly with end-users, identifying their needs, and any un-met needs in the market place. This exploratory research identifies any specific requirements in the market and is tailored specifically to niche markets such as gene therapy, regenerative medicine, personalized medicine, targeted therapeutics and companion diagnostics, drug delivery systems, cosmetic surgery and services, cancer biomarkers and immunotherapy. At KellyScientific, we have a wide range of contacts within these niche areas that provide us with cutting edge insights into a marketplace that is beyond the reach of many. We also travel to international conferences quarterly to source new data and trends from global experts.
Secondary research performed by Kelly Scientific is meticulously scrutinized and analysed prior to integration into a final report. We only use validated and confirmed sources of information from company-specific corporate websites, government websites and documents, annual reports, press releases, international peer-reviewed scientific and medical journals, and research reports. Together both primary and secondary research and also unique insights from the chief analysts and editor alike provide the client with a report that exceeds its competitors.